http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 08 Jul 2024 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html Mon, 08 Jul 2024 07:00:00 -0400 ALDR IMTX IRWD VECT http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html Mon, 08 Jul 2024 07:00:00 -0400 ALDR IMTX IRWD VECT http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html Mon, 08 Jul 2024 07:00:00 -0400 ALDR IMTX IRWD VECT http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html Mon, 08 Jul 2024 07:00:00 -0400 ALDR IMTX IRWD VECT http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html Mon, 08 Jul 2024 07:00:00 -0400 ALDR IMTX IRWD VECT http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html Mon, 08 Jul 2024 07:00:00 -0400 ALDR IMTX IRWD VECT http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html Mon, 08 Jul 2024 07:00:00 -0400 ALDR IMTX IRWD VECT http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html Mon, 08 Jul 2024 07:00:00 -0400 ALDR IMTX IRWD VECT http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html Mon, 08 Jul 2024 07:00:00 -0400 A.00204076 A.31615774 A.50114182 ALDR IMTX O.00222772 O.14731247 O.41101170 VECT http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html Mon, 08 Jul 2024 07:00:00 -0400 A.00204076 A.31615774 A.50114182 ALDR IMTX O.00222772 O.14731247 O.41101170 VECT http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html Mon, 08 Jul 2024 07:00:00 -0400 A.00204076 A.31615774 A.50114182 ALDR IMTX O.00222772 O.14731247 O.41101170 VECT http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html Mon, 08 Jul 2024 07:00:00 -0400 A.00204076 A.31615774 A.50114182 ALDR IMTX O.00222772 O.14731247 O.41101170 VECT http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html Mon, 08 Jul 2024 07:00:00 -0400 A.00204076 A.31615774 A.50114182 ALDR IMTX O.00222772 O.14731247 O.41101170 VECT http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html Mon, 08 Jul 2024 07:00:00 -0400 A.00204076 A.31615774 A.50114182 ALDR IMTX O.00222772 O.14731247 O.41101170 VECT http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html Mon, 08 Jul 2024 07:00:00 -0400 A.00204076 A.31615774 A.50114182 ALDR IMTX O.00222772 O.14731247 O.41101170 VECT http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html Mon, 08 Jul 2024 07:00:00 -0400 A.00204076 A.31615774 A.50114182 ALDR IMTX O.00222772 O.14731247 O.41101170 VECT http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html Mon, 08 Jul 2024 07:00:00 -0400 A.00204076 A.31615774 A.50114182 ALDR IMTX O.00222772 O.14731247 O.41101170 VECT http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html Mon, 08 Jul 2024 07:00:00 -0400 A.00204076 A.31615774 A.50114182 ALDR IMTX O.00222772 O.14731247 O.41101170 VECT http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html Mon, 08 Jul 2024 07:00:00 -0400 A.00204076 A.31615774 A.50114182 ALDR IMTX O.00222772 O.14731247 O.41101170 VECT http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html Mon, 08 Jul 2024 07:00:00 -0400 A.00204076 A.31615774 A.50114182 ALDR IMTX O.00222772 O.14731247 O.41101170 VECT http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html Mon, 08 Jul 2024 07:00:00 -0400 A.00204076 A.31615774 A.50114182 ALDR IMTX O.00222772 O.14731247 O.41101170 VECT http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html Mon, 08 Jul 2024 07:00:00 -0400 A.00204076 A.31615774 A.50114182 ALDR IMTX O.00222772 O.14731247 O.41101170 VECT http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html Mon, 08 Jul 2024 07:00:00 -0400 A.00204076 A.31615774 A.50114182 ALDR IMTX O.00222772 O.14731247 O.41101170 VECT http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html Mon, 08 Jul 2024 07:00:00 -0400 A.00204076 A.31615774 A.50114182 ALDR IMTX O.00222772 O.14731247 O.41101170 VECT http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23439397.html Mon, 08 Jul 2024 07:00:00 -0400 A.00204076 A.31615774 A.50114182 ALDR IMTX O.00222772 O.14731247 O.41101170 VECT